DAR AL DAWA DEVELOPMENT AND INVESTMENT COMPANY

PUBLIC SHAREHOLDING COMPANY

INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

30 JUNE 2025



Ernst & Young Jordan P.O.Box 1140 Amman 11118

Tel: 00 962 6580 0777/00 962 6552 6111

Fax: 00 962 6553 8300 www.ev.com/me

REPORT ON REVIEW OF INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
TO THE BOARD OF DIRECTORS OF DAR AL DAWA DEVELOPMENT AND INVESTMENT COMPANY
PUBLIC SHAREHOLDING COMPANY

AMMAN - THE HASHEMITE KINGDOM OF JORDAN

Introduction

We have reviewed the accompanying interim condensed consolidated financial statements of Dar Al Dawa Development and Investment Company (the "Company") and its subsidiaries (the "Group") which comprise of the interim condensed consolidated statement of financial position as at 30 June 2025 and the related interim condensed consolidated statement of income, interim condensed consolidated statement of comprehensive income for the three and six months then ended, interim condensed consolidated statement of cash flows for the six months then ended and its explanatory notes. The Board of Directors is responsible for the preparation and presentation of these interim condensed consolidated financial statements in accordance with International Accounting Standard 34 "Interim Financial Reporting" (IAS 34). Our responsibility is to express a conclusion on these interim condensed consolidated financial statements based on our review.

Scope of review

We conducted our review in accordance with International Standard on Review Engagements 2410," Review of Interim Financial Information Performed by the independent Auditor of the Entity". A review of Interim financial information consists of making inquiries, primarily of persons responsible for the financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion

Based on our review, nothing has come to the attention that causes us to believe that the accompanying interim condensed consolidated financial statements are not prepared, in all material respects, in accordance with IAS 34.

Amman – Jordan 31 July 2025



DAR AL DAWA DEVELOPMENT AND INVESTMENT COMPANY PUBLIC SHAREHOLDING COMPANY INTERIM CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS AT 30 JUNE 2025

		30 June	31 December
	Notes	2025	2024
		JD (Upoudited)	JD (Audited)
Assets		(Unaudited)	(Audited)
NON-CURRENT ASSETS -			
Property, plant and equipment	3	31,677,576	31,070,538
Projects in progress		559,541	324,299
Intangible assets Investment in an associate		4,496,106	4,571,853
Right of use assets		1,992,492 322,259	1,961,043
Financial assets at fair value through other comprehensive income		4,373	377,173 4,177
Deferred tax assets		2,171,946	2,190,061
		41,224,293	40,499,144
CUPPENT ASSETS			
CURRENT ASSETS - Inventories		04.000.00=	
Trade receivables and other current assets		24,233,395	25,780,184
Amount due from related parties	5	40,842,584 2,759,051	37,999,305 2,124,357
Restricted bank balances	5 6	2,098,295	2,087,353
Cash and balances at banks	6	15,538,431	15,575,516
Net exects bold for cal-		85,471,756	83,566,715
Net assets held for sale		95,057	95,057
TOTAL ASSETS		85,566,813 126,791,106	83,661,772
TO THE MODEL OF		120,791,100	124,160,916
EQUITY AND LIABILITIES			
EQUITY	4		
PARENT COMPANY'S SHAREHOLDERS' EQUITY - Paid-in capital		05 000 000	0.000.000
Statutory reserve		35,000,000 10,000,000	35,000,000 10,000,000
Voluntary reserve		1,992,003	1,992,003
Special reserve		1,268,624	1,268,624
Other reserves		309,465	309,465
Foreign currency translation differences		(7,780,486)	(8,033,785)
Fair value reserve Retained earnings		(257,865)	(257,865)
retained earnings	33	10,571,252 51,102,993	8,852,095
Non-controlling interest		605,487	49,130,537 571,414
NET EQUITY	-	51,708,480	49,701,951
			,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
LIABILITIES NON-CURRENT LIABILITIES -			
Long-term bank loans	7	3,132,030	
Long-term lease liabilities	,	334,764	284,899
End of service indemnity provision		250,580	467,474
	3	3,717,374	752,373
CURRENT LIABILITIES -	•		
Due to banks Revolving loans	6 8	19,116,645	17,217,093
Bank loans instalments maturing within a year	7	25,633,258 3,982,475	26,690,762 1,769,944
Lease liabilities	,	85,034	174,957
Trade payables and other current liabilities		18,573,496	22,662,052
Other provisions	_	3,028,726	4,444,774
Amounts due to a related party	5	7,050	7.10.056
Income tax provision	9	932,410	740,852
Liabilities directly related to assets held for sale		71,359,094 6,158	73,700,434 6,158
		71,365,252	73,706,592
TOTAL LIABILITIES	2	75,082,626	74,458,965
TOTAL SHAREHOLDERS' EQUITY AND LIABILITIES	-	126,791,106	124,160,916

The attached notes from 1 to 13 form part of these interim condensed consolidated financial statements

DAR AL DAWA DEVELOPMENT AND INVESTMENT COMPANY PUBLIC SHAREHOLDING COMPANY INTERIM CONDENSED CONSOLIDATED STATEMENT OF INCOME FOR THE THREE AND SIX MONTHS ENDED 30 JUNE 2025 (UNAUDITED)

	Notes		ee months 30 June	For the si	
	140100	-		ended 3	
		2025	2024	2025	2024
		JD	JD	JD	JD
Revenue from contracts with customers	10	19,110,593	19,290,832	37,313,577	35,795,207
Cost of sales	10	(11,434,557)	(12,023,980)	(21,656,979)	(21,432,922)
Gross profit		7,676,036	7,266,852	15,656,598	14,362,285
Selling and marketing expenses		(3,527,327)	(3,770,947)	(7,529,331)	(7,650,236)
Administrative expenses		(1,823,292)	(1,228,148)	(3,420,559)	(2,812,958)
Research and development expenses		(400,985)	(285,333)	(674,928)	(550,419)
Recoveries from (provision for) expected					
credit losses		38,715	(101,236)	10,317	(136,213)
Other expenses, net		(38,707)	(448,459)	(376,415)	(405,617)
Profit from operations		1,924,440	1,432,729	3,665,682	2,806,842
Group's share of results from an associate		120,669	43,448	31,449	83,339
Employee's termination compensations					
expenses		(58,981)	(11,838)	(177,573)	(50,811)
Interest income		190,196	185,881	368,448	367,317
Finance costs		(1,009,222)	(974,853)	(1,931,141)	(1,853,602)
Profit for the period before income tax		1,167,102	675,367	1,956,865	1,353,085
Income tax for the period	9	(6,187)	36,876	(209,673)	(146,488)
Profit for the period		1,160,915	712,243	1,747,192	1,206,597
Profit for the period attributable to:					
Equity holders of the Parent		1,145,392	691,907	1,719,157	1,166,530
Non-controlling interests		15,523	20,336	28,035	40,067
•		1,160,915	712,243	1,747,192	1,206,597
					.,
		JD/Fils	JD/Fils	JD/Fils	JD/Fils
Basic and diluted earnings per share					
from the profit for the period					
attributable to the Equity holders of					
the Parent	13	0/033	0/02	0/049	0/033

DAR AL DAWA DEVELOPMENT AND INVESTMENT COMPANY PUBLIC SHAREHOLDING COMPANY INTERIM CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME FOR THE THREE AND SIX MONTHS ENDED 30 JUNE 2025 (UNAUDITED)

	For the three		For the six ended 30	
	2025	2024	2025	2024
	JD	JD	JD	JD
Profit for the period	1,160,915	712,243	1,747,192	1,206,597
Add: Other comprehensive income items to be reclassified to statement of income in subsequent periods				
Foreign currency translation differences	118,232	(79,223)	259,337	(30,632)
Total comprehensive income for the period	1,279,147	633,020	2,006,529	1,175,965
Attributable to:				
Equity holders of the Parent	1,259,716	614,663	1,972,456	1,128,009
Non-controlling interest	19,431	18,357	34,073	47,956
	1,279,147	633,020	2,006,529	1,175,965

DAR AL DAWA DEVELOPMENT AND INVESTMENT COMPANY
PUBLIC SHAREHOLDING COMPANY
INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
FOR THE SIX MONTHS ENDED 30 JUNE 2025 (UNAUDITED)

			4	Attributable to	equity holds	Attributable to equity holders of the Parent	nt				
						Foreign					
						currency	Fair			Non-	
	Paid-in	Statutory	Voluntary	Special	Other	translation	value	Retained		controlling	
	capital	reserve	reserve	reserve	reserves	differences	reserve	earnings	Total	interest	Net equity
	QC	Q,	Q	G.	Q.	9	9	9	9	9	=
									!	}	3
Balance as at 1 January	35,000,000	10,000,000	1,992,003	1,268,624	309,465	(8,033,785)	(257,865)	8,852,095	49,130,537	571.414	49 701 951
	×	ř	ij.	ä	×	c	,	1.719.157	1,719,157	28 035	1 747 192
Other comprehensive income											
	3	iĝ		E		253,299	*	J#)	253,299	6.038	259.337
Total comprehensive income											
	ě.	à	•		10	253,299	×	1,719,157	1,972,456	34,073	2,006,529
Balance as at 30 June 2025	35,000,000	10,000,000	1,992,003	1,268,624	309,465	(7,780,486)	(257,865)	10,571,252	51,102,993	605,487	51,708,480
Balance as at 1 January	35,000,000	35,000,000 10,000,000	1,992,003	1,268,624	204,195	(7,662,908)	(257,865)	5,266,709	45,810,758	436,559	46.247.317
	•	,	ű	(101)	6	8	į	1 166 530	1 166 530	40.067	1 206 507
Other comprehensive income										60,61	160,007,1
	ij.		116.7	64	a.c.	(38,521)	*	3	(38,521)	7.889	(30 632)
Total comprehensive income											
		9	(III	10	ı	(38,521)	,	1,166,530	1,128,009	47,956	1,175,965
Balance as at 30 June 2024	35,000,000	10,000,000	1,992,003	1,268,624	204,195	(7,701,429)	(257,865)	6,433,239	46,938,767	484,515	47,423,282

DAR AL DAWA DEVELOPMENT AND INVESTMENT COMPANY PUBLIC SHAREHOLDING COMPANY INTERIM CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE SIX MONTHS ENDED 30 JUNE 2025 (UNAUDITED)

		For the si	x months
	0	ended 3	30 June
	<u>Notes</u>	2025	2024
0		JD	JD
OPERATING ACTIVITIES			
Profit for the period before income tax		1,956,865	1,353,085
Adjustments for -			
Depreciations and amortizations		1,941,694	1 757 257
(Recoveries from) provision for expected credit losses		(10,317)	1,757,357 136,213
Group's share of results from an associate		(31,449)	(83,339)
End of service indemnity provision		84,018	84,017
Provision for expired and near expiry goods		586,889	437,305
Interest income		(368,448)	(367,317)
Finance cost		1,931,141	1,853,602
		.,001,111	1,000,002
Working capital changes -			
Inventories		959,900	(3,487,367)
Related parties		(627,644)	(246,978)
Trade receivables and other current assets		(2,832,962)	(3,575,561)
Accounts payable and other current liabilities		(4,088,556)	3,433,179
Other provisions paid		(1,416,048)	(1,424,162)
Income tax paid	9	(=	(10,894)
End of service indemnity provision paid		(300,912)	(61,614)
Net cash flows used in operating activities	-	(2,215,829)	(202,474)
	-		
INVESTING ACTIVITIES			
Purchase of property, plant and equipment	3	(1,709,504)	(1,460,693)
Intangible assets		(4,534)	#K
Interest income received		368,448	367,317
Projects in progress		(333,593)	(95,632)
Restricted bank balances		(10,942)	- HV
Net cash flows used in investing activities		(1,690,125)	(1,189,008)
FINANCING ACTIVITIES			
Loans settlements		(1,674,428)	(2,233,768)
Loans proceeds		7,018,989	3,309,519
Revolving loans		(1,057,504)	2,976,534
Paid from lease liabilities		(123,166)	(121,000)
Finance cost paid	-	(1,881,276)	(1,853,602)
Net cash flows from financing activities	-	2,282,615	2,077,683
Net (decrease) increase in cash and cash equivalents		(1,623,339)	606 204
Effect of exchange rate changes on cash and cash equivalent			686,201
Cash and cash equivalents at the beginning of the period		(313,298) (1,546,520)	(92,084)
Cash and cash equivalents at the end of the period	6	(3,483,157)	(3,279,363)
and saon equivalents at the end of the period	0	(3,403,107)	(2,685,246)

(1) GENERAL INFORMATION

Dar Al Dawa Development and Investment Public Shareholding Company (The "Company") was established on 17 August 1975 with a paid-in capital of JD 500,000. The Company's Paid-in capital has increased over the years to reach JD 35,000,000 divided into 35,000,000 shares at a par value of JD 1 per share.

The General Assembly of the Company resolved in its extraordinary meeting held on 24 April 2025, to increase the Company's authorized capital by JD 15,000,000, divided into 15,000,000 shares with a par value of JD 1 per share, bringing the Company's authorized capital after the increase to JD 50,000,000, through a private subscription for the Company's shareholders. However, the legal procedures have not been completed as of the date of the interim condensed consolidated financial statements. The Company recorded the capital increase expenses amounting to JD 75,000 as prepaid expenses, to be subsequently deducted from retained earnings upon the completion of legal procedures for the capital increase.

The main objectives of the Company are to manufacture pharmaceutical, chemical and related products and to import medicines. The main objectives of the subsidiaries are the marketing and distributing of Dar Al Dawa products, manufacturing some specialized pharmaceutical products and carrying out investment activities.

The Company's headquarter is located in Na'ur, Amman – the Hashemite Kingdom of Jordan.

These interim condensed consolidated financial statements were approved by the Company's Board of Directors on 27 July 2025.

(2) BASIS OF PREPARATION AND ACCOUNTING POLICIES

(2-1) BASIS OF PREPARATION

The interim condensed consolidated financial statements as at 30 June 2025 have been prepared in accordance with International Accounting Standard 34 (Interim Financial Reporting).

The interim condensed consolidated financial statements are presented in Jordanian Dinar, which is the functional currency of the Company, and the presentation currency of the Group.

The interim condensed consolidated financial statements were prepared under the historical cost basis except for financial assets at fair value through other comprehensive income which are presented at fair value at the date of the interim condensed consolidated financial statements.

The interim condensed consolidated financial statements do not contain all information and disclosures that are required for the annual financial statements prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB), and should be read in conjunction with the Group's annual report as at 31 December 2024. Furthermore, the results of operations for the six months period ended 30 June 2025 do not necessarily reflect the expected results of the operations for the year ending 31 December 2025.

(2-2) CHANGES IN ACCOUNTING POLICIES

The accounting policies used in the preparation of the interim condensed consolidated financial statements are consistent with those used in the preparation of the annual consolidated financial statements for the year ended 31 December 2024, except for the adoption of new standard effective as at 1 January 2025 as shown below:

Lack of exchangeability - Amendments to IAS 21

The amendments to IAS 21 The Effects of Changes in Foreign Exchange Rates specify how an entity should assess whether a currency is exchangeable and how it should determine a spot exchange rate when exchangeability is lacking. The amendments also require disclosure of information that enables users of its financial statements to understand how the currency not being exchangeable into the other currency affects, or is expected to affect, the entity's financial performance, financial position and cash flows.

The amendments are effective for annual reporting periods beginning on or after 1 January 2025. When applying the amendments, the group cannot restate comparative information.

The amendments did not have a material impact on the Group's interim condensed consolidated financial statements.

(2-3) BASIS OF CONSOLIDATION

The interim condensed consolidated financial statements include the financial statements of the Company and its subsidiaries under its control, and control is achieved when the Company is exposed to the variable returns resulting from its investment in the subsidiaries or has rights in such returns, and is able to influence such returns through its authority over the subsidiaries, and transactions, balances, revenues and expenses between the Company and the subsidiaries are excluded. The subsidiaries included in the interim condensed consolidated financial statements are as follows:

Company Name	Main activity	Country of establishment	Percentage of ownership 2025	Percentage of ownership 2024
Dar Al Dawa – Algeria	Marketing	Algeria	100%	100%
Dar Al Dawa – Tunis	Marketing	Tunis	100%	100%
Dar Al Dawa Pharma – Romania	Marketing Financial	Romania	100%	100%
Aldar investment for consulting	investments	Jordan	100%	100%
Nutridar – Public Shareholding Company	Industrial Financial	Jordan	90.4%	90.4%
Al Nahda for Financial Investments* Aldar Jordan for Investments and its	investments	Jordan	40.2%	40.2%
subsidiary Medi Pharma International company –	Investments	Jordan	100%	100%
Algeria Dar Al Dawa Regional Headquarters	Industrial Regional	Algeria	85%	85%
Company**	headquarters	Saudi Arabia	100%	100%

^{*} Al-Nahda for financial investments is under liquidation.

Control is achieved when a Group has rights in variable returns resulting from its association with the investee Group and has the ability to influence these returns through its ability to control the investee Group. The investee Group is controlled only when the following is achieved:

- The Group's control over the investee Group (existing rights that give the Group the ability to direct the relevant activities of the investee company).
- Display of the Group or its rights in the variable returns resulting from its association with the investee Group.
- The ability to exercise control over the investee Group and influence its returns.

Where the Group owns less than a majority of voting rights or similar rights in the investee Company, the Group shall take into account all relevant facts and circumstances to determine whether it has control over the investee Company, including:

- Contractual arrangements with other voting rights holders in the investee Company.
- Rights resulting from other contractual arrangements.
- Current voting rights and possible voting rights of the Group.

^{**} Dar Al-Dawa Regional Headquarters Company was established in the Kingdom of Saudi Arabia during 2024 as a Limited Liability Company.

The Group reassesses whether it controls the investee company and if there are circumstances or facts indicating a change in one or more of the three elements of control.

The financial statements of the subsidiary shall be consolidated from the date of exercising control until such control ceases. The income and expenses of subsidiaries are consolidated in the consolidated interim condensed comprehensive income statement from the date of the Group's control of the subsidiaries until such control ceases.

Profit and loss and every other item of comprehensive income is charged to the shareholders' equity in the parent company and the rights of non-controlling parties, even if this results in a deficit in the equity balance of the non-controlling parties. If necessary, the financial statements of subsidiaries are amended to align their accounting policies with the Group's accounting policies. Assets, liabilities, equity, income, expenses, profits and losses relating to transactions between the Group and its subsidiaries are excluded.

The effect of a change in ownership in the subsidiary that does not result in a loss of control is recorded. When you lose control of the affiliate, the group will:

- Derecognition of assets (including goodwill) and liabilities of the subsidiary
- Derecognition of the rights of non-controlling parties
- Derecognition of foreign currency translation reserves
- Recognition of the fair value of the amounts received
- Recognition of the fair value of the investment held in the subsidiary
- Recognition of profits or losses resulting from the loss of control
- Reclassification of the company's share previously recorded in other comprehensive income items to profit and loss

(3) PROPERTY, PLANT AND EQUIPMENT

The Group purchased property, plant and equipment during the six-months period ended 30 June 2025 with a cost of JD 1,709,504 (30 June 2024: JD 1,460,693).

(4) SHAREHOLDER'S EQUITY

Paid-in Capital

The Company's authorized and subscribed capital is JD 35,000,000 with a nominal value of JD 1 per share as at 30 June 2025.

Statutory reserve

The accumulated amounts of JD 10,000,000 as of 30 June 2025 represent the amounts transferred from the annual net profit before income tax by 10% during the years in accordance with the Companies Law, and it is not distributable to shareholders. The Group may stop transferring amounts to the statutory reserve when the reserve balance reaches 25% of the authorized capital, but it is permissible, with the approval of the Company's general assembly, to continue deducting this annual percentage until this reserve reaches the equivalent of the Company's authorized capital.

Voluntary reserve

The accumulated amounts in this account represent the amounts transferred from the annual net profit before income tax by no more than 20% during the years and is distributable to shareholders.

Special reserve

The accumulated amounts in this account represent the amounts transferred from the annual net profit before income tax by no more than 5% during the years, and it is distributable to shareholders, the special reserve is to be used for the purposes determined by the Board of Directors.

Other reserves

The accumulated amounts of JD 309,465 in this account represent actuarial gains resulting from the revaluation of defined benefit plans through comprehensive income.

Foreign currency exchange differences

The accumulated amounts in this account represent of JD 7,780,486 the foreign currency differences resulting from the translation of the financial statements of foreign subsidiaries.

(5) RELATED PARTIES BALANCES AND TRANSACTIONS

Related parties represent major shareholders, associate, board of directors and companies of which they are principal shareholders. Policies and terms of these transactions are approved by the Group's management.

Below is a summary of related parties included in the interim condensed consolidated statement of financial position are as follows:

	30 June 2025	31 December 2024
	JD	JD
	(Unaudited)	(Audited)
Amounts due from related parties:		,
Zakaria Hawash (Partner in Medi Pharma International)	1,879,005	1,879,005
Al Mufeed Trading – United Arab Emirates (Company		
owned by a board member)	772,733	126,359
Dar Al Dawa Veterinary Industries Limited Liability Company		,
(Associate)	107,313	118,993
i i	2,759,051	2,124,357

	30 June 2025	31 December 2024
	JD	JD
Amounts due to a related party:	(Unaudited)	(Audited)
Al Arabia for Pharmaceutical Research (Company owned by		
a board member)	7,050	
	7,050	3)
Advance payments from customers:	30 June 2025	31 December 2024
	JD (1)	JD
	(Unaudited)	(Audited)
Dara Group for Health (Company owned by a shareholder		
with significant influence)	2 000 000	
The state of the s	3,826,363	8,244,223
Transactions with related parties included in the interim coincome are as follows:	ondensed consolida	ted statement of
	For the six month	ns ended 30 June
	2025	2024
	JD	JD
	(Unaudited)	(Unaudited)
Sales to agents - Dara Group for Health (Company owned by		
	- 500,0000	
a shareholder with significant influence)	5,476,921	6,227,147
Sales to agents - Al Mufeed Trading (Company owned by a		
board member)	2,931,494	2,708,601
Board of directors remuneration and transportation	64,100	59,900
Pharmaceutical studies expenses - Al Arabia for		
Pharmaceutical Research (Company owned by a board		
member)	7,050	~
The following is a summary of the benefits (salaries, bonuses senior executive management:	s and other benefits	s) of the Group's
	For the six month	s ended 30 June
	2025	2024
	JD	JD
	(Unaudited)	(Unaudited)
Coloring and other handite		
Salaries and other benefits	993,458	871,403

(6) CASH AND BALANCES AT BANKS

Cash and balances at banks shown in the interim condensed consolidated statement of financial position represent the following:

	30 June 2025 JD (Unaudited)	31 December 2024 JD (Audited)
Cash on hand Bank balances Short-term deposits*	37,199 4,174,553 11,326,679	132,169 4,414,992 11,028,355
	15,538,431	15,575,516

^{*} This item represents deposits with Arab Bank and Arab Banking Corporation Bank, with an average interest rate of 5.75% - 6% per annum in 2025 (31 December 2024: 6% - 6.25%) and matures within a month to three months.

Cash and cash equivalents for the purpose of preparing the interim condensed consolidated statement of cash flows was as follows:

	30 June 2025 JD (Unaudited)	30 June 2024 JD (Unaudited)
Cash and balances at banks Due to banks* Cash and balances at banks – subsidiary under liquidation	15,538,431 (19,116,645) 95,057	15,469,363 (18,249,666) 95,057
	(3,483,157)	(2,685,246)

^{*} Due to banks represent the facilities granted to the Group's Companies by several banks and in different currencies (Jordanian dinar, Algerian dinar, US dollar and Euro). The total ceilings granted as at 30 June 2025 were equivalent to JD 23,826,238 with an average interest rate that ranges between 5.75% – 8.5% per annum (31 December 2024: a ceiling of JD 23,178,086 with an average interest rate that ranges between 5.5% to 8.25%).

^{**} Restricted bank balances amounting to JD 2,098,295 represents the cash deposited as a collateral in exchange for increasing the ceiling of the overdraft facilities account for Dar Al Dawa - Algeria with the Housing Bank for Trade and Finance – Algeria.

(7) BANK LOANS

dited)	Total	OP	27.361	2.612.500	1,425,000	219,362	915,606	270,146	1,644,530	7,114,505	udited)	Total	Ωſ	78 393	672,000	345,000	222,825	451,726	1.769.944
30 June 2025 (Unaudited)	Long-term	Q	Ŷ	962,500	525,000	ī.		а	1,644,530	3,132,030	31 December 2024 (Audited)	Long-term	<u>무</u>	,		TE.	*	•	
30	Short-term	Q P	27,361	1,650,000	900,000	219,362	915,606	270,146	138	3,982,475	31 De	Short-term	20	78,393	672,000	345,000	222,825	451,726	1,769,944
	Currency		Algerian Dinar	Jordanian Dinar	Jordanian Dinar	US Dollar	Jordanian Dinar	US Dollar	Algerian Dinar			Currency		Algerian Dinar	Jordanian Dinar	Jordanian Dinar	US Dollar	Jordanian Dinar	
(Company name		Medi Pharma International	Dar Al Dawa - Jordan	Dar Al Dawa - Algeria			Company name		Medi Pharma International	Dar Al Dawa - Jordan	Dar Al Dawa - Jordan	Dar Al Dawa - Jordan	Dar Al Dawa - Jordan					
			Societe Generale Bank	Arab Bank (3)	Arab Bank (4)	Housing Bank (1)	Lodeling Balik (2)	Volument All Ballk	Alab ballk					Societe Generale Bank	Arab Bank (1)	Alab Ballk (2) Housing Book (4)	Housing Bank (1)	i iodsiiig Dalik (2)	

Interest rates on bank loans ranges from 3.5% - 8.5% (31 December 2024: between 3.5% - 8.1%) depending on the loan's currency.

The Company mortgaged the 9.8-dunum land of Medi Pharma International plant in Algeria to Societe Generale Bank – Algeria *

DAR AL DAWA DEVELOPMENT AND INVESTMENT COMPANY
PUBLIC SHAREHOLDING COMPANY
NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
30 JUNE 2025 (UNAUDITED)

(8) REVOLVING LOANS

			30 June 202	30 June 2025 (Unaudited)	31 December 2024 (Audited)	2024 (Audited)
				Utilized		Utilized
	Company name	Currency	Ceiling	Balance	Ceiling	Balance
			O.	Qf	Qf	QC
Arab Banking Corporation	Dar Al Dawa – Jordan	US Dollar	5,033,900	4,670,038	3,261,400	3,234,184
Housing Bank	Dar Al Dawa – Jordan	US Dollar	7,799,000	7,209,475	7,799,000	7,718,051
Arab Bank	Dar Al Dawa – Jordan	US Dollar	12,053,000	11,749,959	12,053,000	12,045,617
Arab Jordan Investment Bank	Dar Al Dawa – Jordan	US Dollar	2,836,000	31	2,836,000	1,358,907
Jordan Ahli Bank	Dar Al Dawa – Jordan	US Dollar	3,545,000	169,596	1	Î
Bank of Jordan	Dar Al Dawa – Jordan	US Dollar	3,545,000	415,827	1	
Arab Bank	Nutridar	US Dollar	1,063,500	ā	1,063,500	•
Arab Banking Corporation	Nutridar	US Dollar	3,013,250	1,418,363	3,013,250	2,334,003
			38,888,650	25,633,258	30,026,150	26,690,762

^{*} Interest rates on revolving loans range between 5.68% - 7.4% (31 December 2024: 7.1% - 7.4%).

(9) INCOME TAX PROVISION

The Company calculated the income tax for the results of operations for the periods ended 30 June 2025 and 2024 in accordance with income tax law No. (34) of 2014 and its amendments.

Dar Al Dawa Development & Investment Company - Parent Company

The Company submitted its tax declaration for the years 2023 and 2024. The Income and Sales Tax Department did not review the Company's records up until the date of preparing these interim condensed consolidated financial statements.

The Income and Sales Tax Department has reviewed the Company's records for the years 2021 and 2022, however, its final report has not yet been issued.

The Company obtained a final clearance from the Income and Sales Tax Department until 2020 except for 2017 where the Income and Sales Tax Department reviewed the Company's records for the year 2017, the Company did not accept the approved amount of accumulated losses by the Income and Sales Tax Department in the amount of JD 960,547, therefore the Company registered a lawsuit for objection with the Tax Appeal Court, and the court issued a final decision on 23 June 2025, that approved an accumulated losses amount of JD 10,207,813, which represents the entire amount of the Company's tax loss for the year 2017.

Nutridar Public Shareholding Company

The Company submitted its tax declaration for the years from 2022 up to 2024, and the Income and Sales Tax Department did not review the Company's records until the date of preparing the interim condensed consolidated financial statements.

The Company obtained a final clearance from the Income and Sales Tax Department until 2021.

Al Dar Jordan Investment Company

The Company submitted its tax declaration for the year 2024, and the Income and Sales Tax Department did not review the Company's records until the date of preparing the interim condensed consolidated financial statements.

The Company obtained a final clearance from the Income and Sales Tax Department until 2023.

Dar al Dawa - Romania

The Company submitted its tax declarations for the years from 2022 up to 2024, and the Tax Authority in Romania did not review the Company's records until the date of preparing the interim condensed consolidated financial statements.

The Company obtained a final clearance from the Tax Authority until 2021.

Dar al Dawa - Algeria

The Company submitted its tax declaration for the years from 2021 up to 2024, and the Directorate General of Taxes did not review the Company's records until the date of preparing the interim condensed consolidated financial statements.

During the previous years, the Company recorded a provision of JD 200,000 to cover potential risks for the years from 2021 to 2024. In the opinion of the Company's management and legal counsel, the provision taken is sufficient to meet the liabilities that may arise from such claims.

The Company obtained a final clearance from the General Directorate of Taxes in Algeria until 2020.

The movement on the income tax provision was as follows:

	30 June 2025 JD (Unaudited)	31 December 2024 JD (Audited)
Balances as at the beginning of the period / year Income tax expense for the period / year Prior years tax Income tax paid	740,852 191,558	347,302 399,737 31,419 (37,606)
Balances as at the end of the period / year	932,410	740,852

The income tax for the period shown in the interim condensed consolidated statement of income consists of the following:

	30 June 2025 JD (Unaudited)	30 June 2024 JD (Unaudited)
Income tax for the period Releases from deferred tax assets	191,558 18,115 209,673	- 146,488 146,488

(10) SEGMENT REPORTING OF SALES

The Group is organized for administrative purposes so that the sectors are measured according to the reports that are used by the General Manager and the main decision maker of the Group through the geographical distribution of sales and the geographical distribution of assets and liabilities.

The distribution of sales, cost of sales, gross profit and types of goods sold by geographical areas is as follows:

For the six months ended 30 June 2025 (Unaudited):

	Levant and Iraq JD		rabian Gulf nd Yemen JD	Afr		Europe and Asia JD	Total JD
Net sales	18,106,971		8,709,361	10,4	90,864	6,381	37,313,577
Cost of sales	(10,215,041)		(4,798,287)	(6,64	40,276)	(3,375)	(21,656,979)
Gross profit	7,891,930		3,911,074	3,8	50,588	3,006	15,656,598
					-		
			Food & ir	nfant			
_	Medicine		formul	а	Elim	inations	Total
	JD		JD			JD	JD
Net sales	32,319,	,684 7		94,335	35 (2,700,442)		37,313,577
Cost of sales	(20,431,7	717) (5,87		72,282)		4,647,020	(21,656,979)
Gross profit	11,887,9	967	1,8	22,053	1,946,578		15,656,598
_					-		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
		-	Jordan		Alg	eria	Total
			JD		J	D	JD
Other information							
Depreciation and	amortization		(1,664	l,417)		(277,277)	(1,941,694)
Finance cost	inance cost		(1,402,657)		(528,484)	(1,931,141)	
Recoveries from	•						,
expected credit lo	osses		1	6,251		4,066	10,317
Group's share of	results from an						
associate			3	1,449			31,449
Interest income			368	8,448	34	•	368,448

For the six months ended 30 June 2024 (Unaudited):

	Levant and Iraq JD		abian Gulf nd Yemen JD	Afr		Europe and Asia JD	Total JD
Net sales Cost of sales Gross profit	18,228,551 (11,144,118) 7,084,433		11,149,873 (6,008,924) 5,140,949	(4,27	10,402 77,137) 33,265	6,381 (2,743) 3,638	35,795,207 (21,432,922) 14,362,285
			Food & in	ıfant			
	Medicine		formul	а	Elim	inations	Total
	JD		JD			JD	JD
Net sales	35,868,3	380	6,5	68,162	(6,641,335)	35,795,207
Cost of sales	(21,746,1	47)	(5,15	53,473)		5,466,698	(21,432,922)
Gross profit	14,122,2	233	1,4	14,689	(1,174,637)	14,362,285
			Jordan		Alg	jeria	Total
Other information			JD		·	ID	JD

	Jordan	Algeria	Total
	JD	JD	JD
Other information:			
Depreciation and amortization	(1,457,920)	(299,437)	(1,757,357)
Finance cost	(1,361,877)	(491,725)	(1,853,602)
Provision for expected credit losses	(136,213)	.51	(136,213)
Group's share of results from an	•		(, - · -)
associate	83,339	·	83,339
Interest income	367,317	æ	367,317

The distribution of assets and liabilities by geographical regions is as follows:

			•		- 11 - 11 - 0	
As at 30 June 2025	Jordan	Algeria	Tunisia	Romania	Eliminations	Total
(Unaudited)	JD	JD	JD	JD		JD
Total assets	115,529,368	42,086,660	22,264	573,052	(31,420,238)	126,791,106
Total liabilities	58,018,081	26,385,271	1,744	3,554	(9,326,024)	75,082,626
As at 31 December 2024 (Audited)	Jordan JD	Algeria JD	Tunisia JD	Romania JD	Eliminations	Total
Total assets	115,945,190	43,826,234	22,264	573,054	(36,205,826)	124,160,916
Total liabilities	59,072,909	23,532,533	1,744	3,555	(8,151,776)	74,458,965

(11) CONTINGENT LIABILITIES

At the date of the interim condensed consolidated financial statements, the Group had contingent contractual obligations as follows:

Contingent Liabilities:	30 June 2025 JD (Unaudited)	31 December 2024 JD (Audited)
Letters of credit Bank guarantees Bills of collection Government guaranteed loans	545,788 16,365,142 812,060 2,787,826	762,362 16,463,548 2,521,037 761,352

(12) LAWSUITS HELD AGAINST THE GROUP

There are lawsuits filed against the Group in the amount of JD 5,363,942 as of 30 June 2025 (31 December 2024: JD 5,345,989) within the normal activity of the Group, and in the opinion of the management and its legal advisor, the Group will not have material obligations for these cases.

(13) BASIC AND DILUTED EARNINGS PER SHARE FROM THE PROFIT FOR THE PERIOD

	30 June 2025 (Unaudited)	30 June 2024 (Unaudited)
Profit for the period (JD) Weighted average number of shares during the period	1,719,157	1,166,530
(Share)	35,000,000	35,000,000
Basic and diluted earnings per share from the profit for	JD/Fils	JD/Fils
the period	0/049	0/033